Abstract-Arterial calcification is ubiquitous in vascular disease and is, in part, prevented by matrix Gla protein (MGP).
M
atrix Gla protein (MGP) has been identified as an inhibitor of arterial calcification; gene deletion in mice leads to massive arterial calcification and early death from vascular rupture. 1 Patients with defined mutations in the MGP gene (Keutel syndrome) have widespread calcification in the tracheobronchial tree, and the quality and duration of life appears to be determined by the extent of pulmonary disease. 2, 3 We and others have identified MGP as an inhibitor of bone morphogenetic protein (BMP). 4 -7 Specifically, we have shown that MGP binds and inhibits BMP-2 and -4, which are both detected in calcified atherosclerotic lesions. 8 -11 We have also shown that MGP-deficient cells have increased susceptibility to BMP-2-induced cell differentiation 12 and that MGP interferes with BMP-4 activity in the developing lungs of MGP transgenic mice. 13 MGP is known to be a calcium-binding protein. Calcium is bound through ␥-carboxylated glutamates, so-called "Gla residues," and induces conformational changes in the MGP protein. 4, 14 Warfarin interferes with the vitamin K-dependent ␥-carboxylation and renders MGP nonfunctional, 15 presumably through loss of calcium binding. The majority of the Gla residues are located in the center of the MGP protein (amino acid residue 56 to 71 in human MGP), a region that has been implicated in the binding of BMP. 4 However, the precise amino acid residues involved in BMP binding have not been identified.
In the BMP type I receptor, a phenylalanine residue (Phe85) plays a key role in binding BMP-2. 16 The aromatic side chain of Phe85, with "knob-into-hole" packing, points into a hydrophobic pocket formed at the interfaces of 2 BMP-2 monomers. Similarly, a critical proline residue (Pro35) in the BMP inhibitor Noggin occupies the same pocket, 17, 18 thereby preventing ligand-receptor binding. When examining the protein sequence of human MGP, we found a conserved proline residue (Pro64) centrally located in the BMP-binding region, with 2 Gla residues on each side. This proline residue is conserved in MGP from all species so far examined (human, bovine, mouse, rat, chicken, Xenopus, and fish species including shark and zebrafish) ( Figure I in the online data supplement). We hypothesized that it has a similar role to that of Pro35 in Noggin and that mutagenesis of this proline residue would abolish the ability of MGP to bind and inhibit BMP. We further hypothesized that removal of the Gla residues would affect the ability of MGP to bind and inhibit BMP.
In this study, we show that Pro64 is critical for binding and inhibition of BMP-4 but not for binding of calcium. Deletion of 2 Gla residue on 1 or the other side of Pro64 abolishes the ability to bind and inhibit BMP-4. Removal of calcium ions leads to loss of the ability of MGP to bind BMP-4, suggesting that calcium is essential for the use of Pro64 in binding BMP-4. Only MGP proteins with preserved ability to bind BMP-4 prevent mineralization of calcifying vascular cells. Together, our results suggest that BMP-and calcium binding in MGP are independent but functionally intertwined processes and that the BMP binding is essential for prevention of vascular calcification.
Materials and Methods
An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Cell Culture and Transfection Assays
Bovine aortic endothelial cells (BAECs) and calcifying vascular cells (CVCs) were cultured and transfected as previous described. 7,19 -21 Luciferase assays were performed as previously described 19 and normalized to Renilla. HEK293 and C2C12 cells were obtained from the American Type Culture Collection, and HEK293 cells were transfected using Superfect. Alkaline phosphatase activity and calcium deposition in CVCs were determined as previously described, 20,22 after 2 and 8 days of BMP-4 treatment, respectively.
Vector Constructions and Mutagenesis
The BMP-responsive luciferase reporter gene (BRE-Luc) was obtained from Dr Peter ten Dijke (Leiden University Medical Center, Leiden, The Netherlands). 23 The pN-FLAG-hMGP vector has been described, 7 and the FLAG-tagged zebrafish MGP vector was constructed as described in the online data supplement. Mutagenesis was performed with the QuickSite mutagenesis kit using the primers in supplemental Table I and pN-FLAG-hMGP as template.
Immunoblotting, Immunoprecipitation, and Crosslinking
Immunoblotting and coimmunoprecipitation of BMP-4 and N-FLAG-MGP were performed as previously described. 7, 19 Serumfree conditioned media from transfected HEK293 cells were used in the crosslinking experiments. Conditioned medium was mixed with BMP-4 and chemically crosslinked with disuccinimidyl suberate as described previously. 24 The cross-linked products were analyzed by immunoblotting or protein staining.
Quin2 Staining and Calcium Quantification
Media containing similar concentrations of proteins were concentrated, electrophoresed, and transferred to Hyperbond membranes. Quin2 staining was performed as previously described. 25 Protein bands were excised and digested, and quantification of calcium was performed as previously described. 20 
Statistics
Data were analyzed for statistical significance by ANOVA with post hoc Scheffe's analysis. The analyses were performed using StatView, version 4.51 (Abacus Concepts). All experiments were repeated a minimum of 3 times.
Results

Mutagenesis of Pro64 Abolished the Ability of MGP to Bind and Inhibit BMP-4
To determine whether Pro64 was required for binding and inhibition of BMP-4, we mutated Pro64 in the N-FLAG-MGP expression vector to glycine (N-FLAG-MGP-P64G) using site-directed mutagenesis. We have shown previously that FLAG-tagged MGP is functionally equivalent to nontagged MGP. 6, 7 To compare the effects of N-FLAG-MGP and -MGP-P64G on BMP-4 activity, we cotransfected BAECs with a BMP-responsive reporter gene (BRE-Luc), a Renilla luciferase vector, and increasing amounts of expression constructs for N-FLAG-MGP or -MGP-P64G. The cells were treated with BMP-4 (40 ng/mL) for 24 hours, and luciferase activity was determined and normalized to Renilla luciferase. The results showed that N-FLAG-MGP progressively inhibited luciferase activity induced by BMP-4, whereas N-FLAG-MGP-P64G had no effect on the BMP activity ( Figure 1A) . The experiments were also performed in human aortic endothelial cells with similar results (data not shown). To ensure that the MGP proteins were secreted and to determine whether they interacted with BMP-4, we analyzed the media from BAECs transfected with the maximal amount of MGP construct. First, equal amounts of the media were analyzed by immunoblotting using anti-FLAG-antibodies. The results showed that the level of secreted N-FLAG-MGP and -MGP-P64G were similar ( Figure 1B, top immunoblot) . Second, BMP-4 was added to the N-FLAG-MGP and -MGP-P64G media, and coimmunoprecipitations were performed using anti-BMP-4 or anti-FLAG antibodies. The anti-BMP-4 immunoprecipitates were analyzed by immunoblotting using anti-FLAG-antibodies. Conversely, anti-FLAG immunoprecipitates were analyzed by immunoblotting using anti-BMP-4 antibodies. The results showed that coimmunoprecipitation of N-FLAG-MGP and BMP-4 occurred whether the complex was immunoprecipitated with antibodies to BMP-4 or the FLAG-tag ( Figure 1B) . However, no coimmunoprecipitation was detected for N-FLAG-MGP-P64G and BMP-4 ( Figure 1B) .
To further validate our results, we performed crosslinking experiments using BMP-4 and N-FLAG-MGP or -MGP-P64G. Serum-free conditioned media containing the respective MGP proteins were collected 24 hours after transfection of HEK293 cells. BMP-4 (6 to 10 ng) was added to 80 L of conditioned medium and cross-linked with disuccinimidyl suberate, and protein complexes were analyzed by immunoblotting with anti-FLAG antibodies. Incubation of BMP-4 and N-FLAG-MGP led to the formation of a complex migrating with molecular mass of approximately 60 to 62 kDa that would correspond to a BMP-4 dimer (2ϫ20 to 22 kDa) bound to a MGP dimer (2ϫ10 to 11 kDa) ( Figure 1C ). By contrast, no complex formation was detected when N-FLAG-MGP-P64G was used. Complexes were also immunoprecipitated from large volumes of cross-linked material containing BMP-4 and N-FLAG-MGP or -MGP-P64G using anti-FLAG antibodies and analyzed by SDS-PAGE and protein staining. Again, the major complex was 60 to 62 kDa in samples containing N-FLAG-MGP, but small amounts of complexes of lower molecular masses were also detected ( Figure 1D ). Finally, the protein complexes were analyzed by immunoblotting using anti-BMP-4 antibodies. For these antibodies to work, 50 to 100 ng of BMP-4 was added to 80 L of conditioned medium and cross-linked with disuccinimidyl suberate. The same 60-to 62-kDa complex previously seen with anti-FLAG antibodies and protein staining was detected in samples with N-FLAG-MGP but not with N-FLAG-MGP-P64G. In addition, 2 of the complexes detected by protein staining reacted with anti-BMP-4. Most likely, these corresponded to a BMP-4 monomer bound to either an MGP monomer or an MGP dimer ( Figure 1E ). No complex formation was detected with N-FLAG-MGP-P64G.
Together, the crosslinking results were consistent with the coimmunoprecipitations and suggested that the ability to bind BMP-4 was lost in N-FLAG-MGP-P64G. Furthermore, the results suggested that a dimer of BMP-4 binds to a dimer of MGP.
To ensure that loss of MGP function was not unique to the replacement of proline with glycine, we mutated Pro64 to alanine or tyrosine. Both were unable to replace proline and preserve MGP function (see the online data supplement). Mutagenesis of Pro64 to glycine abolishes the ability of MGP to bind and inhibit the activity of BMP-4. A, BAECs were cotransfected with a constant amount of the BRE-luc reporter gene and increasing amounts of an expression construct for N-FLAG-MGP or N-FLAG-MGP-P64G. The cells were treated with BMP-4 (40 ng/mL) for 24 hours before luciferase activity was determined and normalized to Renilla. Asterisks indicate statistically significant differences compared with control. ***PϽ0.001 (Scheffe's test). B, BMP-4 (100 ng) or carrier was mixed with 1 mL of culture medium collected from BAECs 24 hours after transfection with expression constructs for N-FLAG-MGP, N-FLAG-MGP-P64G, or empty plasmid. The MGP protein level was approximately 40 to 50 ng/mL. BMP-4 was immunoprecipitated (IP) using specific anti-BMP-4 antibodies, and the immunoprecipitates were analyzed by immunoblotting (IB) with anti-FLAG antibodies. Conversely, N-FLAG-MGP proteins were immunoprecipitated with anti-FLAG antibodies, and the immunoprecipitates were analyzed with anti-BMP-4 antibodies. C and E, BMP-4, 6 to 10 ng (C) or 50 to 100 ng (E), was added to 80 L of conditioned medium containing N-FLAG-MGP or N-FLAG-MGP-P64G and chemically cross-linked with disuccinimidyl suberate. Protein complexes were analyzed by immunoblotting using anti-FLAG antibodies (C) or anti-BMP-4 antibodies (E). D, Cross-linked MGP-BMP-4 complexes immunoprecipitated with anti-FLAG antibodies and analyzed by SDS-PAGE and Coomassie blue staining.
Furthermore, mutagenesis of lysine-63 and valine-65, which surround Pro64, or insertion of a serine between lysine-63 and Pro64, did not affect MGP function. The results showed that only the mutants with intact Pro64 bound and inhibited BMP-4, which further supports that Pro64 is essential for MGP function (see online data supplement).
Mutagenesis of Gla Residues Differentially Affects the Ability of MGP to Bind and Inhibit BMP-4
To determine whether the Gla residues are essential for binding and inhibition of BMP-4, we modified the Gla residues by mutating glutamate (Glu)56, -60, -67, and -71 to glycines in the N-FLAG-MGP expression construct using site-directed mutagenesis. We constructed 10 MGP vectors with different combinations of Glu mutations (shown in Figure 2A . We then generated 4 constructs with 1 mutated glutamate on each side of Pro64. The results showed that all mutated MGP proteins retained the ability to inhibit BMP even though there may be differences in the effectiveness of the inhibition ( Figure 2C, left) .
Analysis of the media from the transfected cells showed that the levels of secreted mutated MGP proteins were similar to that of nonmutated MGP (Figure 2A through 2C, right, top anti-FLAG immunoblots). To assess protein interactions, BMP-4 was added to the respective media, and coimmunoprecipitations were performed and analyzed as described above. Overall, the results from the coimmunoprecipitations showed that interaction with BMP-4 was abolished for the same mutated MGP proteins that had lost the ability to inhibit BMP-4. MGP proteins with 2 Gla residues removed on the same side of Pro64 were no longer able to bind BMP-4 ( Figure 2A through 2B, left graphs, PL3 and PR3). MGP proteins with only 1 Glu mutation, or with 1 Glu mutation on each side of Pro64, retained BMP-4 binding ( Figure  2A through 2C) . The results suggest that a minimum of 1 Gla residue on each side of Pro64 is required for BMP-4 inhibition and binding.
Mutagenesis of Pro64 Does Not Affect Calcium Binding by MGP
Other investigators have shown that MGP undergoes conformational changes when it binds calcium. 4, 14 To determine whether mutagenesis of Pro64 to glycine affected calcium binding, N-FLAG-MGP and -MGP-P64G were analyzed using quin2 staining and subsequent quantification of bound calcium. Samples containing similar concentrations of the respective MGP proteins were electrophoresed and transferred to Hyperbond membranes. Troponin C and transforming growth factor-␤1 were included as a calcium-binding and a non-calcium-binding control protein, respectively. The MGP protein bands were visualized using quin2, the bands were excised, and the calcium was released and quantified. The results showed no significant difference in calcium content for N-FLAG-MGP and -MGP-P64G ( Figure 3A) . Low amounts of calcium were detected also after transfection with empty plasmid and were likely derived from endogenous MGP secretion.
To determine whether BMP binding is abolished by calcium removal, N-FLAG-MGP was treated with increasing concentrations of EDTA and then coimmunoprecipitated with BMP-4 as described above. Antigen binding by the antibodies used for immunoprecipitation was not sensitive to calcium concentrations. The results showed that calcium depletion abolished the coimmunoprecipitation of BMP-4 and N-FLAG-MGP ( Figure  3B , right 3 lanes), providing further support that calcium binding in MGP is essential for BMP binding.
Calcium binding is also prevented by mutating all 4 Gla residues or treating the cells with warfarin, which inhibits the vitamin K-dependent ␥-carboxylation. We determined the effect of both interventions on the ability of MGP to bind and inhibit BMP-4. We used an expression construct where all 4 glutamates surrounding Pro64 were mutated to glycines (N-FLAG-MGP-4GlaG), or we treated BAECs with warfarin (15 g/mL) after transfection of the N-FLAG-MGP construct. The effect of the MGP proteins on BMP-4 activity was tested as before by cotransfection of the BMP-responsive luciferase reporter gene, followed by treatment with BMP-4 (40 ng/mL). The results showed that neither N-FLAG-4GlaG nor MGP from warfarin-treated cells inhibited BMP-4 signaling activity ( Figure 3C ). Analysis of the media from the transfected and warfarin-treated cells showed that the MGP proteins were similarly expressed ( Figure 3D , top anti-FLAG immunoblot). However, N-FLAG-MGP-4GlaG and N-FLAG-MGP from warfarin-treated cells did not interact with BMP-4, as determined by coimmunoprecipitation (Figure 3D) , further supporting that calcium binding is critical for BMP binding and BMP inhibition.
Replacement of Pro64 With Phenylalanine Preserves the Ability of MGP to Bind and Inhibit BMP-4
Our hypothesis predicted that replacement of Pro64 by phenylalanine (F) would preserve the MGP function because phenylalanine is the key residue in the binding of BMP-2 by the BMP type I receptor. 16 To test this, we mutated N-FLAG-MGP to -MGP-P64F and then determined the effect of N-FLAG-MGP-P64F on BMP-4 activity by luciferase reporter gene assays. The results showed that N-FLAG-MGP-P64F inhibited BMP-4 activity at least as well as N-FLAG-MGP ( Figure 4A, left) .
Analysis of the media showed that the expression level of N-FLAG-MGP-P64F was similar to that of N-FLAG-MGP ( Figure 4A , right, top anti-FLAG immunoblot). BMP-4 was added to the N-FLAG-MGP and -MGP-P64F media, and protein interactions were examined by coimmunoprecipita- Figure 2 . Mutagenesis of Gla residues differentially affects the ability of MGP to bind and inhibit BMP-4. Left (A through C), BRE-Luc reporter gene assays in BAECs were performed as described in Figure 1A using expression constructs for N-FLAG-MGP and mutant MGP proteins involving glutamate residues upstream of Pro64 (see the figure) (A), N-FLAG-MGP and mutant MGP proteins involving glutamate residues downstream of Pro64 (B), and N-FLAG-MGP and mutant MGP proteins involving glutamate residues on both sides of Pro64 (C). Asterisks indicate statistically significant differences compared with control. ***PϽ0.001 (Scheffe's test). Right (A through C), Coimmunoprecipitations (IP) and immunoblotting (IB) for N-FLAG-MGP, mutant MGP proteins involving glutamate residues upstream of Pro64 and empty plasmid (see figure) (A); N-FLAG-MGP, mutant MGP proteins involving glutamate residues downstream of Pro64 and empty plasmid (B); and N-FLAG-MGP, mutant MGP proteins involving glutamate residues on both sides of Pro64 and empty plasmid (C) were performed as described in Figure 1B using anti-BMP-4 and anti-FLAG antibodies.
tions. The results showed that coimmunoprecipitation was similar for N-FLAG-MGP and -MGP-P64F ( Figure 4A , right), suggesting that proline and phenylalanine are interchangeable in the 64 position.
Zebrafish MGP Does Not Affect BMP-4
Fish MGP lacks the 2 glutamates upstream of the conserved proline (supplemental Figure I) , which suggests that fish MGP does not function as a BMP inhibitor. To determine whether fish MGP binds and inhibits BMP-4 in our system, we constructed expression vectors for untagged and N-terminally FLAG-tagged zebrafish MGP. The effect of the zebrafish MGP on BMP-4 signaling activity was determined using luciferase reporter gene assays in BAECs and compared to human MGP. The results showed that untagged and FLAG-tagged zebrafish MGP had no effect on BMP-4 signaling ( Figure 4B, left) . Analysis of the media showed a similar expression level of the 2 MGP proteins ( Figure 4B , right, top anti-FLAG immunoblot). BMP-4 was then added to the respective medium and coimmunoprecipitations were performed. The results showed no coimmunoprecipitation of BMP-4 and N-FLAG zebrafish MGP ( Figure 4B , right) suggesting that fish MGP is not a BMP inhibitor.
MGP With Lost Ability to Bind and Inhibit BMP-4 Does Not Prevent Mineralization in Calcifying Vascular Cells
MGP is known as an inhibitor of vascular calcification. To determine whether mutant MGP that has lost the ability to bind BMP-4 still inhibits calcification, we used the calcifying CVCs, a well-established model of vascular calcification that mineralizes in response to BMP. 20, 26 The CVCs were tran- Aliquots from cells transfected with empty plasmid were used for comparison. The proteins were allowed to renature and bind calcium. Calcium binding was visualized by quin2, the protein bands were excised, and the calcium was released by 25 mmol/L HCl and quantified. Troponin C and transforming growth factor-␤1 were used as a positive and negative control, respectively. B, Coimmunoprecipitations (IP) and immunoblotting (IB) for N-FLAG-MGP in the presence of increasing concentrations of EDTA and for empty plasmid were performed as described in Figure 1B using anti-BMP-4 and anti-FLAG antibodies that were not sensitive to calcium changes. C, BRE-Luc reporter gene assays in BAEC were performed as described in Figure 1A using expression constructs for N-FLAG-MGP and N-FLAG-MGP-4GlaG proteins. Assays involving N-FLAG-MGP were performed in the absence or presence of warfarin (15 g/mL) in culture medium. D, Co-IP and IB for N-FLAG-MGP (produced in the absence or presence of warfarin in culture medium), N-FLAG-MGP-4GlaG, and empty plasmid were performed as described in Figure 1B using anti-BMP-4 and anti-FLAG antibodies. Asterisks indicate statistically significant differences compared with control; ***PϽ0.001 (Scheffe's test).
siently transfected with empty vector (EV) or expression constructs for wild-type or mutant N-FLAG-MGP proteins. Expression of the MGP proteins was verified by immunoblotting of culture media collected 48 hours after transfection using anti-FLAG antibodies. The expression of the different MGP proteins was similar ( Figure 5C and 5D ). The CVCs were treated for up to 8 days with BMP-4 (20 ng/mL). The activity of alkaline phosphatase, an early marker of osteogenic differentiation, and calcium mineral deposition were determined after 2 and 8 days, respectively. The results showed that both alkaline phosphatase and mineral deposition were only inhibited in CVCs transfected with MGP proteins known to bind and inhibit BMP-4 ( Figure 5C and 5D) . The results suggest that binding of BMP-4, but not of calcium, is essential for the prevention of vascular calcification by MGP.
Similarly, we also determined that N-FLAG-MGP-P64G was unable to prevent BMP-induced osteogenic differentiation in the pluripotent C2C12 cells, as determined by morphology and alkaline phosphate activity (see online data supplement).
Discussion
MGP is best known as an inhibitor of vascular calcification and may interfere with BMP-signaling during the process of calcification. Others and we have demonstrated that MGP binds and inhibits BMP-2 and -4 in vascular cells. 4 -7 We have also shown that MGP-deficient cells have an increased susceptibility for BMP-2-induced cell differentiation 12, 20 and that excess MGP interferes with BMP-4 activity in the developing lungs of MGP transgenic mice. 13 In this study, we show that Pro64 in MGP is critical for binding of BMP-4 but not of calcium. Deletion of 2 Gla residues on 1 or the other side of Pro64 also results in lost inhibition and binding of BMP-4, suggesting that the Gla residues contribute to the conformation required for BMP binding.
Proline and phenylalanine have been shown to be critical for BMP binding by Noggin and the BMP type I receptor, respectively. 16 -18 Our results show that MGP binds and inhibits BMP-4 with either proline or phenylalanine in the 64 position, suggesting that the binding between MGP and BMP-4 occurs according to the same knob-into-hole model that has been proposed for Noggin and the BMP type I receptor based on crystal structures. 16, 18 Differences in activity between different MGP mutants were noted in the BMP-4 activity curves (see, eg, Figure 2 ). It is possible that these curves reflect the fit between MGP and BMP-4, that a stronger inhibition of BMP-4 may indicate a better fit and vice versa. The relative ability of a specific MGP mutant to inhibit BMP-4, as compared with other mutants, was consistent among experiments, although the absolute differences varied. However, the immunoprecipitation experiments did not detect any differences in the ability to bind BMP-4, which may be attributable to technical factors. The MGP media used for immunoprecipitations were all collected from cells transfected with the maximal amount of MGP construct, but BMP-4 was still added in excess for the BMP-4 antibodies to work optimally. Thus, even if the affinity for BMP-4 of some MGP mutants were low, it may not be detected because of the excess BMP-4. In addition, the immunoblotting was technically difficult to perform because of the proximity of the light chains (from precipitating antibodies), which may have affected transfer and detection of BMP-4 and MGP. Further experimentation will be needed to clarify the "molecular fit" between BMP-4 and MGP.
Overall, the crosslinking data support the formation of a complex containing a BMP-4 dimer and an MGP dimer. Small amounts of presumed intermediary complexes containing a BMP-4 monomer with 1 or 2 MGP were also detected when the immunoblots were analyzed with anti-BMP-4 antibodies ( Figure 1D ).
Our data suggest that the Gla residues are intimately involved in achieving the conformation necessary for BMP binding, which has previously been suggested by the results of Sweatt et al 5 that show that BMP-2 binds to the Glacontaining regions of MGP only in the presence of calcium. Similarly, the Gla residues have been implicated in structurefunction in other proteins. In protein C, an anticoagulant, and factor VII, a procoagulant, the Gla residues have been implicated in membrane association. 27 In osteocalcin, a calcium-binding protein of bone, 3 Gla residues are part of a helical motif and participates directly in the binding of calcium and the adsorption of osteocalcin to hydroxylapatite surfaces. 28 The spacing of the Gla residues in osteocalcin (at positions 17, 21, and 24) places all Gla side chains on the same face of 1 ␣ helix, closely paralleling the interatomic separation of calcium in the hydroxylapatite lattice. Interestingly, the spacing of MGP Gla residues 56 and 60, and 67 and 71, respectively, is identical to the spacing of the osteocalcin Gla residues, suggesting that the Gla residues in MGP are part of helical motifs on both sides of Pro64.
The mechanism of MGP in vascular calcification continues to be under debate. On one hand, it has been proposed that MGP inhibits vascular calcification by binding calcium ions, thereby preventing mineral precipitation or crystal growth. 29 On the other hand, others and we have proposed that MGP inhibits BMP-signaling, thereby preventing unwanted cellinduced mineralization. 4, 6 The early and profound changes of smooth muscle cells into chondrocyte-like cells reported for the MGP knockout mice 1, 30, 31 are consistent with increased susceptibility to BMP in the MGP-deficient cells. Our previ- ous studies also showed an increased susceptibility to BMP-2-induced cell differentiation in vitro, 12 which is further supported by the findings in this study. Our results showed that only those MGP proteins with the ability to bind BMP-4 inhibited mineralization ( Figure 5) . Specifically, the mutant N-FLAG-MGP-P64G, which was shown to bind calcium ( Figure 3A) , did not prevent calcium deposition in CVCs. Thus, our results support the hypothesis that MGP prevents vascular calcification by inhibiting BMP rather than by binding calcium. However, our results suggest that calcium is intimately involved in enabling MGP to inhibit BMP by binding to the Gla residues. We speculate that the MGP may have different conformational states. On one hand, Gla residues may bind to membranes or mineral crystals and possibly preclude BMP binding. On the other hand, binding of soluble calcium may induce structural transitions that allow BMP binding.
Although MGP is similar to Noggin in that both may be considered morphogens and both has proline residues that are critical for BMP binding, MGP differs in its dependency on calcium for BMP binding. Because MGP is able to interact with vitronectin in extracellular matrix, 32 it is possible that MGP is more aimed at regulating local BMP and may be more sensitive to variations in calcium concentrations. MGP may be released by cleavage of the C terminus, which has been shown to be missing in MGP purified from tissue (see Figure 6 for hypothetical model). 33 Noggin, on the other hand, may have a larger range of action and be independent of calcium concentrations.
Our results may also relate to the pathogenesis of a debilitating form of arteriolar calcification, so-called calcific uremic arteriolopathy, or calciphylaxis, which may affect dialysis patients. 34 BMP-4 has been identified in the perivascular areas of calciphylaxis lesions, 35 and warfarin has been proposed to be a risk factor for calciphylaxis. 34 Pericytes, which are perivascular cells in small vessels, are similar to CVCs 8 and are known to express MGP. 36 It is possible that a loss of functional MGP, eg, after warfarin treatment, triggers a BMP-4 -induced process that leads to calciphylaxis.
Our results may have implications for MGP function in different species. Mouse MGP lacks the first ␥-carboxylated Glu residue in the BMP-binding region when compared with human MGP. However, mutagenesis of this Glu residue did not diminish inhibition or binding of BMP-4, and we would therefore expect MGP to function similarly in mouse and human. This is supported by the similarities in phenotype between the MGP knockout mouse and patients with the Keutel syndrome, which include underdevelopment of facial bones, short stature, and abnormal cartilage calcification. 1, 3 On the other hand, fish MGP lacks both Gla residues upstream of Pro64, and our results suggest that zebrafish MGP does not inhibit BMP. It is still possible that it would bind zebrafish BMP-4 even though there is a very high degree of homology between human and zebrafish BMP-4. It is intriguing that MGP from species with lungs all have conserved glutamates upstream of the conserved proline (supplemental Figure I ), whereas none of the fish species do. It is possible that MGP took on the role as a BMP inhibitor as lungs were developed. We have previously shown that MGP has a regulatory effect on vascular development in the lungs 13 that contributes to the coordination of airway and vascular development.
In summary, our study shows that the presence of Pro64 and a sufficient number of Gla residues in MGP are essential for binding of BMP-4 and suggests that BMP-and calcium binding in MGP are independent but functionally intertwined processes. Our study also shows that the BMP binding is essential for prevention of vascular calcification by MGP.
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